BACKGROUND: There has not been any prospective evaluation of the safety and tolerability of regadenoson (REG)-stress in patients with end-stage renal disease (ESRD). METHODS: From the pooled database of two identically designed randomized, double-blinded, placebo-controlled clinical trials, ASSUAGE and ASSUAGE-CKD (IV-aminophylline vs placebofollowing REG-stress), we extracted the placebo-treated subjects to form 2 study groups: ESRD (dialysis or GFR < 15 mL/minute/1.73 m(2)) and control (GFR ≥ 30). The incidence of REG adverse effects and the hemodynamic and ECG responses to REG-stress were compared. RESULTS: We identified 146 ESRD subjects and 97 controls. There was no significant difference in the incidence of the composite of any REG adverse effect [ESRD 108 (74%) vs control 73 (75%), P = .82]. ESRD patients seem to have excess incidences of diarrhea [42 (29%) vs 14 (14%), P = .009] and fewer events of dizziness [28 (19%) vs 43 (44%), P < .001]. There were no serious adverse events in either group. There was no significant difference in the incidence of ST-segment deviation, tachyarrhythmias, atrioventricular block, or hypotension. CONCLUSION: This is the first prospective study to confirm the safety and tolerability of REG in patients with ESRD.
RCT Entities:
BACKGROUND: There has not been any prospective evaluation of the safety and tolerability of regadenoson (REG)-stress in patients with end-stage renal disease (ESRD). METHODS: From the pooled database of two identically designed randomized, double-blinded, placebo-controlled clinical trials, ASSUAGE and ASSUAGE-CKD (IV-aminophylline vs placebo following REG-stress), we extracted the placebo-treated subjects to form 2 study groups: ESRD (dialysis or GFR < 15 mL/minute/1.73 m(2)) and control (GFR ≥ 30). The incidence of REG adverse effects and the hemodynamic and ECG responses to REG-stress were compared. RESULTS: We identified 146 ESRD subjects and 97 controls. There was no significant difference in the incidence of the composite of any REG adverse effect [ESRD 108 (74%) vs control 73 (75%), P = .82]. ESRDpatients seem to have excess incidences of diarrhea [42 (29%) vs 14 (14%), P = .009] and fewer events of dizziness [28 (19%) vs 43 (44%), P < .001]. There were no serious adverse events in either group. There was no significant difference in the incidence of ST-segment deviation, tachyarrhythmias, atrioventricular block, or hypotension. CONCLUSION: This is the first prospective study to confirm the safety and tolerability of REG in patients with ESRD.
Authors: Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani Journal: Circulation Date: 2002-01-29 Impact factor: 29.690
Authors: Robert C Hendel; Timothy M Bateman; Manuel D Cerqueira; Ami E Iskandrian; Jeffrey A Leppo; Brent Blackburn; John J Mahmarian Journal: J Am Coll Cardiol Date: 2005-11-09 Impact factor: 24.094
Authors: Gong Zhao; Axel Linke; Xiaobin Xu; Manuel Ochoa; Francis Belloni; Luiz Belardinelli; Thomas H Hintze Journal: J Pharmacol Exp Ther Date: 2003-09-03 Impact factor: 4.030
Authors: Vasken Dilsizian; Henry Gewirtz; Nicholas Paivanas; Anastasia N Kitsiou; Fadi G Hage; Nathan E Crone; Ronald G Schwartz Journal: J Nucl Cardiol Date: 2015-05-15 Impact factor: 5.952